To explore mitochondrial dysregulation in oral squamous cell carcinoma (OSCC) and evaluate therapeutic strategies targeting mitochondrial functions, highlighting its significance in treatment resistance.
Key Findings:
OSCC exhibits frequent resistance to conventional therapies linked to mitochondrial dysregulation, necessitating alternative treatment approaches.
Mitochondrial DNA mutations and metabolic reprogramming contribute to the resistant phenotype, indicating potential targets for intervention.
Alterations in TP53 and EGFR signaling are implicated in mitochondrial dysfunction and apoptotic resistance, suggesting pathways for therapeutic exploration.
Somatic mtDNA mutations are recurrent in OSCC and may influence therapeutic vulnerability, highlighting the need for personalized treatment strategies.
Interpretation:
Mitochondrial dysfunction plays a critical role in OSCC pathogenesis and treatment resistance, suggesting that targeting mitochondrial pathways could offer new therapeutic avenues, warranting further investigation.
Limitations:
The predictive value and causal roles of mtDNA mutations remain incompletely defined, which may limit their utility in clinical settings.
Current evidence is primarily derived from broader cancer literature rather than OSCC-specific studies, potentially affecting the applicability of findings.
Conclusion:
A cautious translational roadmap is proposed for testing mitochondria-directed strategies in OSCC, emphasizing the need for biomarker-enriched clinical development to maximize therapeutic efficacy.
